Welcome to our dedicated page for Nanobiotix S.A. SEC filings (Ticker: NBTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nanobiotix S.A.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nanobiotix S.A.'s regulatory disclosures and financial reporting.
Nanobiotix S.A. completed the full exercise of underwriters’ over-allotment option in its global equity offering, bringing aggregate gross proceeds to approximately $100 million (about €86.1 million) before fees and expenses. The option exercise adds 33,805 Additional ADSs at $38.98 each, corresponding to €33.60 per ordinary share. In total, the Global Offering comprises 2,218,467 ordinary shares, including 259,178 in ADS form, plus 345,099 pre-funded warrants. Nanobiotix plans to allocate between 50-60% of net proceeds to its Nanoprimer and other platforms, less than 10% to JNJ-1900 (NBTXR3), and 30-40% to general corporate purposes. The company states that, with this financing and existing cash, it expects to fund operations into 2029.
Nanobiotix S.A. is conducting a global offering of 2,184,662 ordinary shares and 345,099 pre-funded warrants, consisting of a U.S. offering of 225,373 ADSs (one ADS = one ordinary share) and a European offering of 1,959,289 ordinary shares plus 345,099 pre-funded warrants.
The public offering price is €33.60 per ordinary share (ADS price $38.98), and each pre-funded warrant is priced at €33.57 with an exercise price of €0.03 per ordinary share. Net proceeds are estimated at approximately €79.12 million (before expenses), and the underwriters have a 30‑day option to purchase up to 33,805 additional ordinary shares, which would increase estimated net proceeds to €80.89 million.
Shares outstanding were 48,410,068 ordinary shares as of December 31, 2025. The pre-funded warrants are not expected to trade on any exchange and contain beneficiary ownership caps that limit exercises above specified thresholds.
Nanobiotix S.A. priced an oversubscribed global follow-on offering raising expected gross proceeds of about €85.0 million (approximately $98.6 million) before fees, with potential to reach about €87.8 million if the over-allotment option is fully exercised.
The deal comprises 225,373 ADSs at $38.98 each in the U.S., plus 1,959,289 ordinary shares at €33.60 and 345,099 pre-funded warrants at €33.57 in Europe and other markets. Each pre-funded warrant can be exercised in cash for one share at €0.03 until May 26, 2036.
The company plans to allocate between 50-60% of net proceeds to its Nanoprimer and other platforms, less than 10% to JNJ-1900 (NBTXR3), and 30-40% to general corporate purposes, and expects its cash resources plus this raise to fund operations into 2029. Illustrative tables show dilution for non-participating holders, with a 1% stake falling to about 0.95% on a fully diluted post-transaction basis and equity per share improving from -€1.75 to around -€1.66.
Nanobiotix S.A. reports that trading in its ordinary shares on the regulated market of Euronext Paris has resumed as of 3:30 p.m. Paris time / 9:30 a.m. New York time on May 21, 2026.
Trading had been halted earlier that day at the company’s request in connection with a previously announced global securities offering. This global offering includes a U.S. public offering of American Depositary Shares, each representing one ordinary share with a nominal value of €0.03, and an international offering of ordinary shares and pre-funded warrants to qualified investors in Europe and certain other countries outside the United States and Canada.
Nanobiotix S.A. reports that trading of its ordinary shares on Euronext Paris is being temporarily halted at the company’s request. The halt is linked to a previously announced global equity financing that combines a U.S. public offering of American Depositary Shares with an international offering of ordinary shares and pre-funded warrants to qualified investors outside the United States and Canada.
The pause is intended to allow final allocation to investors and announcement of pricing for this global offering. Trading on Euronext Paris is expected to resume on May 21, 2026, at about 3:30 p.m. Paris time, which corresponds to 9:30 a.m. in New York.
Nanobiotix S.A. is launching an approximately €75 million (about $87 million) global follow-on equity offering, split between a U.S. ADS sale and an International Offering of ordinary shares and pre-funded warrants to qualified investors. All securities will be newly issued by the company via a capital increase without preferential subscription rights under prior shareholder delegations. The company may grant underwriters a 30-day option for up to 15% additional ADSs and has set a 90-day lock-up for itself and board members. Net proceeds are expected to be used mainly to advance its Nanoprimer and other platforms, with smaller portions for JNJ-1900 (NBTXR3) development and general corporate purposes, while management retains broad discretion over allocation. The company highlights potential dilution and trading volatility as key risks for existing shareholders.
Nanobiotix S.A. provides clinical and pipeline updates for its radioenhancer JNJ-1900 (NBTXR3) and Curadigm Nanoprimer platform in connection with an underwritten offering. The Phase 2 CONVERGE trial in unresectable stage 3 NSCLC reported early Part 1 data in seven patients, with an 85.7% objective response rate, 57.1% complete response rate and 100% disease control after chemoradiotherapy, JNJ-1900 and durvalumab, though the company cautions these preliminary results from a small cohort should not be seen as predictive.
The pivotal Phase 3 NANORAY-312 head and neck cancer trial, sponsored by Johnson & Johnson, was amended to remove an interim analysis and bring forward the final analysis at 335 events, with maintained endpoints and improved statistical power for progression-free survival at 92% and overall survival at 80%. Nanobiotix notes it may receive up to approximately $200 million in development and regulatory milestones from J&J over the next few years if head and neck and lung programs meet specified goals.
The company also highlights Curadigm Nanoprimer preclinical data showing that pretreatment in a mouse model increased systemic exposure and reduced liver clearance of lipid nanoparticle DNA immunotherapies, while decreasing hepatic toxicity and inflammatory responses. These findings, along with multiple ongoing collaborations and new patent filings, support further exploration of Curadigm with advanced intravenously delivered therapeutics.
Nanobiotix S.A. is conducting a global offering of securities targeting €75,000,000 in ordinary shares and pre-funded warrants, delivered in the U.S. as ADSs and outside the U.S. as ordinary shares and pre-funded warrants.
The supplement describes ADSs listed as NBTX on Nasdaq and ordinary shares listed as NANO on Euronext Paris, pre-funded warrants exercisable for one ordinary share at an exercise price of €0.03, transfer and exercisability limits tied to a Beneficial Ownership Limitation, and an underwriter option to purchase additional shares. The company reported €52.8M cash and cash equivalents and a net tangible book deficit of €(84.5M) as of December 31, 2025. Use of proceeds is stated as accelerating development of JNJ-1900 (NBTXR3), advancing the Curadigm Nanoprimer platform, and general corporate purposes.
Nanobiotix S.A. reported early Part 1 results from the Johnson & Johnson-sponsored CONVERGE randomized Phase 2 trial of nanoradioenhancer JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer. In seven patients completing concurrent chemoradiotherapy, JNJ-1900, and durvalumab, the overall response rate was 85.7% (6/7) and the complete response rate was 57.1% (4/7), compared with historically very low complete response rates under current standard of care. Disease control rate reached 100% (7/7), with no progressive disease and responses deepening over time, suggesting potential for durable benefit. JNJ-1900 is a one-time intratumoral hafnium oxide nanoparticle injection activated by radiotherapy, being developed across multiple solid tumors, including a global Phase 3 head and neck cancer trial and supported by a global co-development and commercialization agreement with Johnson & Johnson.
Nanobiotix S.A. reports that the FDA has accepted a protocol amendment for the pivotal NANORAY-312 global Phase 3 study in head and neck cancer, sponsored by Johnson & Johnson. The amendment removes the planned interim analysis and changes the final analysis to be based on fewer events and to occur earlier than originally designed. Nanobiotix believes this could accelerate and broaden the global registration path for its radiotherapy-activated nanoparticle candidate JNJ-1900 (NBTXR3), potentially allowing earlier revenue generation from its licensing deal. The company notes it is eligible for hundreds of millions in aggregate milestone payments over the next few years, contingent on development and regulatory achievements in head and neck and lung cancer programs.